KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Debt to Equity (2017 - 2023)

Historic Debt to Equity for Bionano Genomics (BNGO) over the last 7 years, with Q3 2023 value amounting to $0.08.

  • Bionano Genomics' Debt to Equity rose 15449.76% to $0.08 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.08, marking a year-over-year increase of 15449.76%. This contributed to the annual value of $0.04 for FY2022, which is N/A changed from last year.
  • Latest data reveals that Bionano Genomics reported Debt to Equity of $0.08 as of Q3 2023, which was up 15449.76% from $0.05 recorded in Q2 2023.
  • Bionano Genomics' 5-year Debt to Equity high stood at $5.56 for Q4 2019, and its period low was -$14.44 during Q2 2019.
  • Its 5-year average for Debt to Equity is -$0.53, with a median of $0.04 in 2021.
  • Within the past 5 years, the most significant YoY rise in Bionano Genomics' Debt to Equity was 52399.8% (2019), while the steepest drop was 55223.74% (2019).
  • Over the past 5 years, Bionano Genomics' Debt to Equity (Quarter) stood at $5.56 in 2019, then plummeted by 91.63% to $0.47 in 2020, then tumbled by 91.19% to $0.04 in 2021, then decreased by 8.21% to $0.04 in 2022, then skyrocketed by 123.39% to $0.08 in 2023.
  • Its Debt to Equity stands at $0.08 for Q3 2023, versus $0.05 for Q2 2023 and $0.04 for Q1 2023.